Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 313

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 19
Chunk 313
---
 co-commercialization of IPH5201. Under the agreement, AstraZeneca paid the

F-14

Company a $ 50.0 26.0 24.0 5.0 5.0

On June 1, 2022, the Company signed an amendment to the collaboration and license option agreement IPH5201 concluded with AstraZeneca in October 2018. Subsequently, the Company announced on June 3, 2022 the progress of IPH5201 towards a study of Phase 2 in lung cancers for which the Company will be the sponsor. In accordance with the amendment signed on June 1, 2022, the Company is eligible for a milestone payment of $ 5.0

Upon exercise of its option under the agreement, AstraZeneca is committed to pay an option exercise fee of $ 25.0 800.0 300 500 50 50.0 5.0 30 50 50

Refer to Notes 2. p and 13 for accounting description.

d) Agreement related to additional preclinical molecules with AstraZeneca

In October 2018, the Company granted to AstraZeneca four 20.0 17.4

During 2022 first semester, the Company received from AstraZeneca a notice that it will not exercise its option to license the four programs covered in the "Future Programs Option Agreement". Innate has now regained full rights to further develop the four 20.0 17.4

Refer to Notes 2. p and 13 for accounting description.

F-15

e) Agreements related to avdoralimab with Novo Nordisk and with AstraZeneca

2017 avdoralimab in-licensing agreement with Novo Nordisk A/S

In July 2017, the Company signed an exclusive license agreement with Novo Nordisk A/S relating to avdoralimab. Under the agreement, Novo Nordisk A/S granted the Company a worldwide, exclusive license to develop, manufacture and commercialize pharmaceutical products that contain or comprise an anti-C5aR antibody, including avdoralimab. The Company made an upfront payment of € 40.0 37.2 2.8 1.0 369.0

Refer to Notes 2. h, 2. j and 6 for accounting description.

2018 avdoralimab AstraZen